Harvard Business Review

JUNE 9, 2017

Equally troublesome, almost all policies focus exclusively on payments and finances but ignore the powerful influence of careerism and other non-financial motives that may compromise objectivity far more than financial incentives. For academics, publishing and obtaining grants are key to promotion and career advancement.

Conflict of Interest 8

Conflict of Interest Pharmaceuticals Policies Industry 8

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products. Experimentation is vital.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

MARCH 24, 2011

In the early 1980s, for example, at least some partners — Bob Waterman, co-author of In Search of Excellence , among them — counseled gradual, quiet expansion, this to maintain the top-flight quality of the consultancy's people and its work. Was it only ten years ago that the profits of the top 10 U.S. And what risks did he run?

McKinsey 13

McKinsey Consultative Waterman Intellectual Capital 13

Harvard Business Review

JANUARY 10, 2013

For example, application of complex financial accounting rule — FAS 133 relating to derivatives — led to expensive restatements in numerous businesses. initiative — prohibitions against off-label marketing under the False Claims Act — swept through the pharmaceutical industry. billion restatement.

Finance 8

Finance Banking Press Release Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 19, 2016

Imagine, for example, that you’re a pharmaceutical CEO deciding whether to recall a new drug. In these cases, running the numbers and grasping what they tell you is important, but it isn’t enough. With gray area problems, you have to look hard at the economics and look past the economics. How should you make this decision?

ROI 8

ROI Long-term Conflict of Interest Pharmaceuticals 8